The Israeli-American biotechnology company is also currently conducting a Phase III clinical trial for the treatment of amyotrophic lateral sclerosis (ALS).

The reality of ALS is painful. It's a condition that causes the muscles to degenerate gradually, leading to death with several years. An Israeli study is now showing significant results in what may be a breakthrough for sufferers of the neurodegenerative disease.

A new understanding of what takes place at the cellular level during the development of neurodegenerative diseases, such as Parkinson’s and Alzheimer’s offers promise towards possible new treatments, according to the Hebrew University.

Israeli Channel Two audiences last night were moved to see an ailing rabbi, who had been diagnosed with ALS, able to walk and talk again after being treated with Brainstorm's 'NurOwn.'

BG Negev Technologies and Applications, the technology transfer company of Ben Gurion University of the Negev, has raised $1 million from a US private equity fund, to develop therapies for neurodegenerative diseases. The funding will support a study conducted by the university’s Department of Immunology and Microbiology, which might be useful for prolonging lifespans for […]

The Israeli biotechnology company BrainStorm announced successful results in its clinical trial for a drug against ALS (Amyotrophic Lateral Sclerosis) - a fatal neurodegenerative disease also known as Lou Gehrig's disease.